Trial Scorecard: REDEFINE 1 and 2 Structural Biophysics Guided Computational Design of Semaglutide Analogues to Enhance GLP 1R Activation Article (Preprint v1) by Wei Li Qeios Type 2 diabetes: Combo of semaglutide and cagrilintide reduces blood sugar and leads to weight loss Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors Acta Pharmacologica Sinica In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet